Dublin (Business Wire)
Research and Markets (http://www.researchandmarkets.com/research/e46934/morocco_pharmaceut) has announced the addition of the “Morocco Pharmaceuticals and Healthcare Report Q3 2011” report to their offering.
This report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Morocco’s pharmaceuticals and healthcare industry.
BMI View: Unlike many states in the Middle East and North Africa (MENA) region, Morocco does not have extensive natural oil and gas reserves. Consequently, the state’s finances are stretched and there is a need to realise greater efficiencies in the healthcare system before the introduction of the RAMED scheme at the end of 2011. These savings will come in the form of increased generic medicines prescriptions and a reduction in drug prices.
Headline Expenditure Projections:
- Pharmaceuticals: MAD8.67bn (US$1.05bn) in 2010 to MAD9.48bn (US$1.08bn) in 2011; +9.3% in local currency terms and +3.0% in US dollar terms. 2010 sales down significantly from Q211, growth forecast up in light of increase in public fiscal expenditure.
- Healthcare: MAD39.76bn (US$4.80bn) in 2010 to MAD43.00bn (US$4.89bn) in 2011; +8.1% in local currency terms and +1.8% in US dollar terms. Forecast down slightly from Q211 because of delays in enacting the RAMED scheme.
- Medical devices: MAD1.74bn (US$210mn) in 2010 to MAD1.90bn (US$216mn) in 2011; +9.2% in local currency terms and +2.9% in US dollar terms. Forecast up slightly from Q211 because of increase in public fiscal expenditure.
Key Trends & Developments:
- Morocco’s government has announced a set of concessions for public sector workers to alleviate protests threatening the country’s stability. The concessions are thought to be worth MAD43bn (US$5.4bn). This money is likely to be spent on salaries, pensions and improving working conditions across the state sector.
- In May 2011, Caisse Nationale des Organismes de Prvoyance Sociale (CNOPS), Morocco’s compulsory health insurance scheme for public sector workers, legislated to repay any prescribed medication at the price of generic drugs, making it in the direct interest of patients to buy generic medicines.
Key Topics Covered in this Report:
SWOT Analysis
Pharmaceutical Business Environment Ratings
Market Summary – Morocco
Industry Forecast Scenario
Competitive Landscape
Company Profiles
Country Snapshot: Morocco Demographic Data
Glossary
BMI Methodology
Companies Mentioned:
- Sothema
- Laprophan
- Promopharm
- Multinational Company Profiles
- Sanofi-Aventis
- Pfizer
- GlaxoSmithKline
